130
Participants
Start Date
November 7, 2023
Primary Completion Date
July 31, 2026
Study Completion Date
November 30, 2026
Antibody-Drug Conjugate
MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
University of Pennsylvania, Abramson Cancer Center, Philadelphia
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
NEXT Oncology, Fairfax
ACTIVE_NOT_RECRUITING
Carolina BioOncology Institute, Huntersville
RECRUITING
Medical University of South Carolina (MUSC), Charleston
RECRUITING
PRISMA Health, Institute for Translational Oncology, Greenville
RECRUITING
Winship Cancer Institute, Emory University, Atlanta
COMPLETED
Horizon Oncology Research, Lafayette
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
NEXT Oncology, Irving
RECRUITING
NEXT Oncology, Austin
RECRUITING
University of Colorado, Anschutz Cancer Pavilion (ACP(, Aurora
RECRUITING
Comprehensive Cancer Center of Nevada, Las Vegas
RECRUITING
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
MBrace Therapeutics
INDUSTRY